Case Western Reserve University

Northwestern University

Kent State University

James P Basilion

Xinning Wang

Clemens Burda

Thomas J Meade

Natalie Walker

Jihua Hao

Kirti Dhingra

Sarah Grace Kamper

Songping D Huang

Christopher A Flask

Yongxiu Li

Richard Agnes

Zhenghong Lee

Dong Luo

A polymerizable phthalocyanine compound having the formula (I) or a PSMA-targeted phthalocyanine compound conjugate thereof having the formula (V).

Photodynamic therapy composition

PSMA targeted conjugate compounds, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein.

PSMA targeted conjugate compounds and uses thereof

Prostate-specific membrane antigen (PSMA) targeted compounds having formula (I), nanoclusters formed thereof, pharmaceutical compositions comprising a plurality of these compounds, and methods for treating and detecting cancers in a subject are described herein.

PSMA ligand targeted compounds and uses thereof

A composition for imaging a cell includes a first imaging probe and a second imaging probe that include respectively a first reporter moiety and a second reporter moiety. The first reporter moiety and the second reporter moiety form a signaling complex that produces a detectable signal when the first imaging probe and second imaging probe complex with first and second biomarkers of the cell.

Composition and methods for imaging cells

PSMA targeted compounds, pharmaceutical compositions comprising these compounds, and methods for treating and detecting cancers in a subject are described herein.

PSMA targeted compounds and uses thereof

A method of treating a PSMA expressing cancer in a subject includes (a) administering to the subject a PSMA-targeted phthalocyanine conjugate compound having the formula (I), (b) detecting the PSMA-targeted phthalocyanine compound bound to and/or complexed with the prostate cancer cells to determine the location and/or distribution of the prostate cancer cells in the subject, (c) surgical resection of the detected cancer, and (d) irradiating the PSMA-targeted phthalocyanine compound at the site of surgical resection, thereby inducing the cytotoxic effects of the phthalocyanine compound on residual prostate cancer cells following surgical resection.

A probe for imaging EGFR expressing cells includes an EGFR targeting moiety, a reporter moiety, and a hydrophilic linker that links the EGFR targeting moiety to the reporter moiety. The hydrophilic linker enhances solubility of the probe in an aqueous media as well as binding affinity of the probe to EGFR expressing cells.

Targeted non-invasive imaging probes of EGFR expressing cells

A composition for treating a disorder in a subject includes a polyethylene glycolylated (PEGylated) nanoparticle, at least one hydrophobic therapeutic agent coupled to the surface of the nanoparticle; and at least one targeting moiety coupled to polyethylene glycol of the nanoparticle for targeting the composition to a cell associated with disorder.

Targeted nanoparticle conjugates

A phthalocyanine compound or targeted conjugate thereof having the formula (I).

Compounds that are PSMA ligands, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein.

PSMA ligands and uses thereof

A system for detecting tumor margins includes a topical protease-specific, fluorescence imaging probe that is activatable by enzymatic activation to produce a visually differentiated signal upon topical application to a targeted cancer cell that secretes an enzyme that activates the protease-specific, fluorescence imaging probe, an applicator for topically administering the imaging probe to the cancer cell; and an imaging device to detect activation of the imaging probe administered to the cancer cell.

Growing community of inventors

Shaker Heights, OH, United States of America

James P Basilion